Privately owned biopharmaceutical company pioneering the use of anti-somatostatin vaccine use. Our products (under the trademark Somatovac) have been used for treatment of metaboloic conditions, such as obesity, and productivity enhancement (livestock). Braasch has a US and international patent portfolio for our core technology (protein), application as vaccines, adjuvants and metabolic adjustment.